Fig. 4
From: GG-NER’s role in androgen receptor signaling inhibitor response for advanced prostate cancer

Construction and validation of the NECGS model. A&D. KM plots and risk curves showing the correlation between NECGS and ARSI response, including ACTL6A, PARP2, and RUVBL1 expression in training and validation sets. B&E. Univariate and multivariate Cox regression analyses of NECGS’s impact on ARSI response in training and validation sets. C&F. ROC curve analyses of NECGS’s predictive efficacy for ARSI response in training and validation sets